Abstract
Purpose
To evaluate the role of medical imaging in predicting local recurrence of giant cell tumour of bone (GCTB) by assessing the preoperative imaging features of GCTB around the knee.
Methods
Forty-eight consecutive GCTBs in the proximal tibia and distal femur treated with curettage were prospectively enrolled. Patients were grouped in terms of their imaging features on radiography, computed tomography (CT) and magnetic resonance imaging (MRI). All patients were followed up for at least two years after surgery. The association between preoperative imaging features and local recurrence was investigated. Imaging features were retrospectively studied by correlation analysis. The differences between rates were tested by the Chi square and Fisher exact tests; independent factors were determined by multivariate logistic regression analysis.
Results
Cystic change and adjacent soft tissue invasion were associated with a higher rate of local recurrence compared to the negative groups (P < 0.05). Cystic change was identified as an independent risk factor for local recurrence of GCTB (P < 0.05). Expansibility was correlated with the “soap bubble” sign and the fluid–fluid level (P < 0.05); the “soap bubble” sign was correlated with osteosclerosis and the fluid–fluid level (P < 0.05); cortical bone involvement was correlated with adjacent soft tissue invasion (P < 0.05); and cystic change was correlated with the fluid–fluid level (P < 0.05).
Conclusion
Cystic change was an independent risk factor for local recurrence of GCTB. Adjacent soft tissue invasion might indirectly relate to local relapse. A cluster of association relationships between imaging features was revealed.
Similar content being viewed by others
References
Siddiqui MA, Seng C, Tan MH (2014) Risk factors for recurrence of giant cell tumours of bone. J Orthop Surg (Hong Kong) 22:108–110
van der Heijden L, Dijkstra PD, van de Sande MA, Kroep JR, Nout RA, van Rijswijk CS, Bovee JV, Hogendoorn PC, Gelderblom H (2014) The clinical approach toward giant cell tumor of bone. Oncologist 19:550–561
Hu P, Zhao L, Zhang H, Yu X, Wang Z, Ye Z, Wu S, Guo S, Zhang G, Wang J, Ning X, Hu Y, Zhang Y (2016) Recurrence rates and risk factors for primary giant cell tumors around the knee: a multicentre retrospective study in China. Sci Rep 6:36332
Zambo I, Vesely K (2014) WHO classification of tumours of soft tissue and bone 2013 the main changes compared to the 3rd edition. Ceskoslovenska Patol 50:64–70
Enneking WF (1986) A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 204:9–24
Cowan RW, Singh G (2013) Giant cell tumor of bone: a basic science perspective. Bone 52:238–246
Girolami I, Mancini I, Simoni A, Baldi GG, Simi L, Campanacci D, Beltrami G, Scoccianti G, D’Arienzo A, Capanna R, Franchi A (2016) Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series. J Clin Pathol 69:240–247
McGough RL, Rutledge J, Lewis VO, Lin PP, Yasko AW (2005) Impact severity of local recurrence in giant cell tumor of bone. Clin Orthop Relat Res 438:116–122
Lausten GS, Jensen PK, Schiodt T, Lund B (1996) Local recurrences in giant cell tumour of bone. Long-term follow up of 31 cases. Int Orthop 20:172–176
Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH (2011) Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 469:591–599
Arbeitsgemeinschaft K, Becker WT, Dohle J, Bernd L, Braun A, Cserhati M, Enderle A, Hovy L, Matejovsky Z, Szendroi M, Trieb K, Tunn PU (2008) Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 90:1060–1067
Chanchairujira K, Jiranantanakorn T, Phimolsarnti R, Asavamongkolkul A, Waikakul S (2011) Factors of local recurrence of giant cell tumor of long bone after treatment: plain radiographs, pathology and surgical procedures. J Med Assoc Thail Chotmaihet Thangphaet 94:1230–1237
Kivioja AH, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer HC, Jorgensen PH, Bergh P, Folleras G (2008) Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop 79:86–93
Abat F, Almenara M, Peiro A, Trullols L, Bague S, Gracia I (2015) Giant cell tumour of bone: a series of 97 cases with a mean follow-up of 12 years. Rev Esp Cir Ortop Traumatol 59:59–65
Teixeira LE, Vilela JC, Miranda RH, Gomes AH, Costa FA, de Faria VC (2014) Giant cell tumors of bone: nonsurgical factors associated with local recurrence. Acta Orthop Traumatol Turc 48:136–140
O’Donnell RJ, Springfield DS, Motwani HK, Ready JE, Gebhardt MC, Mankin HJ (1994) Recurrence of giant-cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am 76:1827–1833
Ghert MA, Rizzo M, Harrelson JM, Scully SP (2002) Giant-cell tumor of the appendicular skeleton. Clin Orthop Relat Res 400:201–210
Turcotte RE, Wunder JS, Isler MH, Bell RS, Schachar N, Masri BA, Moreau G, Davis AM, Canadian Sarcoma G (2002) Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res 397:248–258
Gouin F, Dumaine V, French S, G-G Bone Tumor Study Groups (2013) Local recurrence after curettage treatment of giant cell tumors in peripheral bones: retrospective study by the GSF-GETO (French Sarcoma and Bone Tumor Study Groups). Orthop Traumatol Surg Res 99:S313–S318
Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH (2011) Recurrent giant cell tumor of long bones: analysis of surgical management. Clin Orthop Relat Res 469:1181–1187
Murphey MD, Nomikos GC, Flemming DJ, Gannon FH, Temple HT, Kransdorf MJ (2001) From the archives of AFIP. Imaging of giant cell tumor and giant cell reparative granuloma of bone: radiologic-pathologic correlation. Radiographics 21:1283–1309
Wang CS, Lou JH, Liao JS, Ding XY, Du LJ, Lu Y, Yan L, Chen KM (2013) Recurrence in giant cell tumour of bone: imaging features and risk factors. Radiol Med 118:456–464
Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR Jr (2013) Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiogr Rev Publ Radiol Soc North Am Inc 33:197–211
Jiang X, Engelbach JA, Yuan L, Cates J, Gao F, Drzymala RE, Hallahan DE, Rich KM, Schmidt RE, Ackerman JJ, Garbow JR (2014) Anti-VEGF antibodies mitigate the development of radiation necrosis in mouse brain. Clin Cancer Res 20:2695–2702
Giglio P, Gilbert MR (2003) Cerebral radiation necrosis. Neurologist 9:180–188
Wong CS, Van der Kogel AJ (2004) Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv 4:273–284
Krober SM, Greschniok A, Bohm P, Kaiserling E (1998) Giant cell tumor of bone. Morphological, immunohistochemical, morphometric and DNA flow cytometric findings. Verh Dtsch Ges Pathol 82:279–283
Chen L, Ding XY, Wang CS, Si MJ, Du LJ, Lu Y (2014) Triple-phase dynamic MRI: a new clue to predict malignant transformation of giant cell tumor of bone. Eur J Radiol 83:354–359
Taylor RM, Kashima TG, Knowles HJ, Athanasou NA (2012) VEGF, FLT3 ligand. PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: implications for giant cell tumour pathobiology, Lab Invest 92:1398–1406
Zhang J, Dong J, Yang Z, Ma X, Zhang J, Li M, Chen Y, Ding Y, Li K, Zhang Z (2015) Expression of ezrin, CD44, and VEGF in giant cell tumor of bone and its significance. World J Surg Oncol 13:168
Kumta SM, Huang L, Cheng YY, Chow LTC, Lee KM, Zheng MH (2003) Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci 73:1427–1436
Chen L, Ding XY, Wang CS, Si MJ, Du LJ, Zhang WB, Lu Y (2014) In-depth analysis of local recurrence of giant cell tumour of bone with soft tissue extension after intralesional curettage. Radiol Med 119:861–870
Van Dyck P, Vanhoenacker FM, Vogel J, Venstermans C, Kroon HM, Gielen J, Parizel PM, Bloem JL, De Schepper AM (2006) Prevalence, extension and characteristics of fluid-fluid levels in bone and soft tissue tumors. Eur Radiol 16:2644–2651
Meana Moris AR, Garcia Gonzalez P, Fuente Martin E, Gonzalez Suarez C, Moro Barrero L (2010) Primary giant cell tumor of soft tissue: fluid-fluid levels at MRI (2010:3b). Eur Radiol 20:1539–1543
Wang H, Wan N, Hu Y (2012) Giant cell tumour of bone: a new evaluating system is necessary. Int Orthop 36:2521–2527
Kremen TJ Jr, Bernthal NM, Eckardt MA, Eckardt JJ (2012) Giant cell tumor of bone: are we stratifying results appropriately? Clin Orthop Relat Res 470:677–683
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study was funded by the Science and Technology Commission of Shanghai Municipality (Project Number: 134119a2402).
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical standards
This article does not contain any studies with human participants or animals performed by any of the authors.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Additional information
The original version of this article has been revised: First and last names of the fourth author were incorrect. Now, it has been corrected.
An erratum to this article is available at http://dx.doi.org/10.1007/s11547-017-0760-8.
Rights and permissions
About this article
Cite this article
He, Y., Wang, J., Zhang, J. et al. A prospective study on predicting local recurrence of giant cell tumour of bone by evaluating preoperative imaging features of the tumour around the knee joint. Radiol med 122, 546–555 (2017). https://doi.org/10.1007/s11547-017-0745-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11547-017-0745-7